416 related articles for article (PubMed ID: 21505336)
1. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?
Lorenzen S; Lordick F
Curr Opin Oncol; 2011 Jul; 23(4):396-402. PubMed ID: 21505336
[TBL] [Abstract][Full Text] [Related]
2. HER2 testing in gastric cancer.
Albarello L; Pecciarini L; Doglioni C
Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
[TBL] [Abstract][Full Text] [Related]
3. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
Bang YJ
J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer.
Lordick F
Future Oncol; 2011 Feb; 7(2):187-99. PubMed ID: 21345138
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
[TBL] [Abstract][Full Text] [Related]
6. HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options.
Koltz BR; Hicks DG; Whitney-Miller CL
Biotech Histochem; 2012 Jan; 87(1):40-5. PubMed ID: 21745161
[TBL] [Abstract][Full Text] [Related]
7. Targeted HER2 treatment in advanced gastric cancer.
Jørgensen JT
Oncology; 2010; 78(1):26-33. PubMed ID: 20185938
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab in gastric cancer.
Okines AF; Cunningham D
Eur J Cancer; 2010 Jul; 46(11):1949-59. PubMed ID: 20542421
[TBL] [Abstract][Full Text] [Related]
9. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
10. [HER2 and gastric cancer: a novel therapeutic target for trastuzumab].
Bouché O; Penault-Llorca F
Bull Cancer; 2010 Dec; 97(12):1429-40. PubMed ID: 21134821
[TBL] [Abstract][Full Text] [Related]
11. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
[TBL] [Abstract][Full Text] [Related]
12. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.
Wang T; Hsieh ET; Henry P; Hanna W; Streutker CJ; Grin A
Hum Pathol; 2014 May; 45(5):970-5. PubMed ID: 24656529
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
14. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
15. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
Hechtman JF; Polydorides AD
Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
[TBL] [Abstract][Full Text] [Related]
16. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.
Kaur A; Dasanu CA
Expert Opin Pharmacother; 2011 Nov; 12(16):2493-503. PubMed ID: 21967344
[TBL] [Abstract][Full Text] [Related]
17. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target.
De Vita F; Giuliani F; Silvestris N; Catalano G; Ciardiello F; Orditura M
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S11-5. PubMed ID: 21129604
[TBL] [Abstract][Full Text] [Related]
18. [HER2 testing and targeted therapy in advanced gastric cancer].
Höhler T; Rüschoff J; Ridwelski K; Moehler M
Onkologie; 2010; 33 Suppl 4():26-30. PubMed ID: 20431310
[TBL] [Abstract][Full Text] [Related]
19. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend.
Ferretti G; Felici A; Papaldo P; Fabi A; Cognetti F
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):56-62. PubMed ID: 17218853
[TBL] [Abstract][Full Text] [Related]
20. Isolated CNS relapse in human epidermal growth factor receptor 2-positive esophagogastric cancer: effective treatment with trastuzumab after failure of surgery and radiotherapy.
Geldart T; Astras G
J Clin Oncol; 2011 Aug; 29(23):e664-5. PubMed ID: 21646609
[No Abstract] [Full Text] [Related]
[Next] [New Search]